This committee is the key entry point for studies of new imaging agents and the development of early trials to evaluate new imaging agents, approaches, and plans for their broader application. At least one representative from each disease-oriented committee or working group is appointed as a core member. This committee seeks leaders in imaging, regardless of their institution’s membership status in the Group.
David A. Mankoff, MD, PhD
University of Pennsylvania and the Abramson Cancer Center
Anthony F. Shields MD, PhD
Wayne State University and the Barbara Ann Karmonos Cancer Center
|Cancer Control and Outcomes Program|
|Therapeutic Studies Program|
|Biomarker Sciences Program|